California investment firm Vivo Capital has secured $740 million in commitments to be aimed at preclinical- and clinical-stage life sciences companies. The Vivo Opportunity Fund is an evergreen public ...
A mouse study shows CAR-T cells can be engineered in vivo with precise gene editing, a potential breakthrough that could cut ...
Vivodyne cofounders Andrei Georgescu (left) and Dan Huh. Washington Square-based biotech company Vivodyne raised $38 million in its quest to develop lab-grown human organs. Khosla Ventures led the ...
PM PT, Viva Biotech (01873.HK) optimizes the Proteina-Complexa model in advancing the design of mini-binders targeting ActRIIA, a receptor critical in muscle wasting and lean mass imbalance, aiming to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results